These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29087150

  • 1. Impact of formulary restrictions on medication use and costs.
    Shen X, Stuart BC, Powers CA, Tom SE, Magder LS, Perfetto EM.
    Am J Manag Care; 2017 Aug 01; 23(8):e265-e274. PubMed ID: 29087150
    [Abstract] [Full Text] [Related]

  • 2. Does the offer of free prescriptions increase generic prescribing?
    Stuart B, Hendrick F, Dougherty JS, Xu J.
    Am J Manag Care; 2017 Jun 01; 23(6):e193-e201. PubMed ID: 28817295
    [Abstract] [Full Text] [Related]

  • 3. Impact of formulary restrictions on medication intensification in diabetes treatment.
    Stuart BC, Slejko JF, Rueda JD, Cooke CE, Shen X, Roberto P, Ciarametaro M, Dubois R.
    Am J Manag Care; 2018 May 01; 24(5):239-246. PubMed ID: 29851442
    [Abstract] [Full Text] [Related]

  • 4. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
    Stuart B, Hendrick FB, Xu J, Dougherty JS.
    Health Serv Res; 2017 Jun 01; 52(3):1185-1206. PubMed ID: 27324201
    [Abstract] [Full Text] [Related]

  • 5. Impact of medicare part D plan features on use of generic drugs.
    Tang Y, Gellad WF, Men A, Donohue JM.
    Med Care; 2014 Jun 01; 52(6):541-8. PubMed ID: 24824538
    [Abstract] [Full Text] [Related]

  • 6. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E, Kyrychenko P, Matlin OS, Avila JP, Brennan TA, Shrank WH.
    J Clin Pharm Ther; 2016 Feb 01; 41(1):64-9. PubMed ID: 26778812
    [Abstract] [Full Text] [Related]

  • 7. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF, Merrell K, Hargrave E, Summer L.
    Health Aff (Millwood); 2012 Oct 01; 31(10):2266-75. PubMed ID: 23048108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A, Lalani HS, Vaduganathan M, Navar AM, Fonarow GC, Das SR, Pandey A.
    JAMA Cardiol; 2021 Jan 01; 6(1):92-96. PubMed ID: 32902560
    [Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
    Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH.
    Ann Intern Med; 2014 Sep 16; 161(6):400-7. PubMed ID: 25222387
    [Abstract] [Full Text] [Related]

  • 12. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
    Patel RA, Walberg MP, Woelfel JA, Amaral MM, Varu P.
    Medicare Medicaid Res Rev; 2013 Sep 16; 3(2):. PubMed ID: 24753963
    [Abstract] [Full Text] [Related]

  • 13. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
    Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM.
    Arch Intern Med; 2006 Feb 13; 166(3):332-7. PubMed ID: 16476874
    [Abstract] [Full Text] [Related]

  • 14. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG, Worley K, Louder A, Ward M, Graham J.
    J Manag Care Pharm; 2013 Jun 13; 19(5):374-84. PubMed ID: 23697475
    [Abstract] [Full Text] [Related]

  • 15. Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.
    Li P, Schwartz JS, Doshi JA.
    J Am Heart Assoc; 2016 Nov 11; 5(11):. PubMed ID: 27836822
    [Abstract] [Full Text] [Related]

  • 16. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL, Worley K, Meah Y, Everhart D.
    J Manag Care Spec Pharm; 2017 Mar 11; 23(3):299-306. PubMed ID: 28230454
    [Abstract] [Full Text] [Related]

  • 17. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA.
    JAMA Intern Med; 2021 Dec 01; 181(12):1605-1611. PubMed ID: 34661600
    [Abstract] [Full Text] [Related]

  • 18. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS.
    JAMA Intern Med; 2016 Jun 01; 176(6):763-8. PubMed ID: 27159336
    [Abstract] [Full Text] [Related]

  • 19. Encouraging generic use can yield significant savings.
    Zimmerman C.
    Find Brief; 2012 Nov 01; 15(8):1-3. PubMed ID: 23213854
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.